To evaluate the effectiveness of transscleral diode laser cyclophotocoagulation in a population of patients with refractory glaucoma, comparing the results between the slow-coagulation continuous-wave (SC-CPC) and micropulse laser treatment (MP-LT) techniques.

ORLANDO — While there will always be points of friction in the market, unmet needs in ophthalmology will ultimately yield innovation, according to a speaker at Eyecelerator@AAO. In an ophthalmic market overview, Kristen Harmon Ingenito, MBA, CEO of Market Scope, valued the ophthalmic market at $48.7 billion in 2024, with an expected combined annual growth rate of 4.5% through 2029. “Our fastest growing segment continues to be the glaucoma surgical device space, and we’re also seeing a lot of growth in IOLs,” Ingenito said. “Retina pharmaceuticals continues to be our slowest growing market, but

ORLANDO — While there will always be points of friction in the market, unmet needs in ophthalmology will ultimately yield innovation, according to a speaker at Eyecelerator@AAO. In an ophthalmic market overview, Kristen Harmon Ingenito, MBA, CEO of Market Scope, valued the ophthalmic market at $48.7 billion in 2024, with an expected combined annual growth rate of 4.5% through 2029. “Our fastest growing segment continues to be the glaucoma surgical device space, and we’re also seeing a lot of growth in IOLs,” Ingenito said. “Retina pharmaceuticals continues to be our slowest growing market, but

Eye, Published online: 16 October 2025; doi:10.1038/s41433-025-04067-8Double trouble: exploring Oguchi disease with anomalous optic disc

Eye, Published online: 16 October 2025; doi:10.1038/s41433-025-03996-8Treatment intervals with first-generation anti-vascular endothelial growth factor drugs: evaluating the unmet need in a real-world neovascular age-related macular degeneration national database

Eye, Published online: 16 October 2025; doi:10.1038/s41433-025-04066-9Associations between sleep patterns and diabetic retinopathy: insights from cross-sectional and longitudinal evidence

This case report discusses a diagnosis of medication-associated maculopathy in a 44-year-old woman receiving exemestane treatment after breast cancer resection.

This case report discusses a diagnosis of posterior lenticonus with intralenticular cracks found during a school vision screening in a girl aged 8 years referred for decreased visual acuity in the left eye.

This case report describes the grading and effects of myopic traction maculopathy in eyes with high myopia.

Mission Statement: To be the indispensable source of ophthalmic knowledge by promptly publishing innovative, clinically relevant research through consistent and authoritative peer review and, thereby, to be the first choice of authors for their important manuscripts.

Ocular-motor impairment is a common and often early clinical indicator across the full spectrum of traumatic brain injury, manifesting from cranial nerve dysfunction to subtle deficits in smooth pursuit and binocular convergence. This vulnerability is attributed to the distributed anatomy of the oculomotor system, which spans cortical, subcortical, and brainstem regions. Consequently, ocular-motor performance has gained traction as a sensitive and noninvasive biomarker of neural integrity following exposure to subconcussive repetitive head impacts (RHI).

This study examines the association between repetitive head impacts and oculomotor control across a single division I American football season.

This cohort study examines whether there is an association between exposure to metformin and the development of any age-related macular degeneration (AMD) and its progression to geographic atrophy or neovascular AMD.

Numerous children around the world live with myopia. Daily topical atropine is a simple intervention to slow the progression of myopia in children. However, there is a gap in the evidence about the effectiveness and safety of long-term atropine use. Liu et al aimed to fill this evidence gap with data on 606 923 children with myopia. Two-thirds of the children in the study were prescribed atropine eye drops and followed up for a mean of 13.2 years. Children who were not prescribed atropine were followed up for a mean of 14.1 years. This evidence on long-term effect and safety of atropine is crucial for children, their parents, and physicians to make informed decisions.

Editor’s note: This is a developing news story. Please check back soon for updates. EssilorLuxottica added to its medical technology portfolio with the acquisition of Ikerian AG, a Swiss health tech company doing business under the name RetinAI, according to a press release. The company’s flagship product is RetinAI Discovery, a clinical software platform for managing patient data and imagery, with AI-based disease monitoring capabilities. It also makes Discovery Unity, another data management platform geared toward clinical studies and pharmaceutical research and development. “RetinAI

Editor’s note: This is a developing news story. Please check back soon for updates. EssilorLuxottica added to its medical technology portfolio with the acquisition of Ikerian AG, a Swiss health tech company doing business under the name RetinAI, according to a press release. The company’s flagship product is RetinAI Discovery, a clinical software platform for managing patient data and imagery, with AI-based disease monitoring capabilities. It also makes Discovery Unity, another data management platform geared toward clinical studies and pharmaceutical research and development. “RetinAI

Iantrek launched AlloFlo Uveo, a bio-interventional surgical treatment that targets the uveoscleral pathway in patients with glaucoma, according to a press release. “Over the past 15 years, glaucoma surgeons have seen dozens of technologies become available for enhancing the trabecular outflow pathway,” Adam Szaronos, CEO of Iantrek, told Healio. “But as we all know, the eye has two natural outflow pathways. This is where the biggest unmet need is and is a complementary fit for every MIGS patient as efficacy inevitably wanes. AlloFlo Uveo provides a reproducible way to access the uveoscleral

There was a lot of excitement when teprotumumab-trbw became the first drug approved for the treatment of thyroid eye disease in January 2020. The availability of teprotumumab-trbw (Tepezza, Amgen) has changed the landscape of treatment in thyroid eye disease. Image: Eisha Gupta, MD. Printed with permission. “Tepezza has been a game changer in how thyroid eye disease is now managed,” Arti Bhan, MD, FACE, a Healio | Endocrine Today Editorial Board Member and division head of endocrinology at Henry Ford Health System, said in an interview. “We have patients who have high clinical activity scores

Iantrek launched AlloFlo Uveo, a bio-interventional surgical treatment that targets the uveoscleral pathway in patients with glaucoma, according to a press release. “Over the past 15 years, glaucoma surgeons have seen dozens of technologies become available for enhancing the trabecular outflow pathway,” Adam Szaronos, CEO of Iantrek, told Healio. “But as we all know, the eye has two natural outflow pathways. This is where the biggest unmet need is and is a complementary fit for every MIGS patient as efficacy inevitably wanes. AlloFlo Uveo provides a reproducible way to access the uveoscleral

Eye, Published online: 15 October 2025; doi:10.1038/s41433-025-04079-4A 20-year review of orbital biopsy at the Newcastle Eye Centre

We hypothesised that HM patients would exhibit impaired emotional processing capabilities due to disrupted amygdala connectivity

A retrospective study found significant value in reducing the time to repair of ocular injuries sustained during battle among US military members.

Publication date: Available online 15 October 2025 Source: Experimental Eye Research Author(s): Dongchun Xie, Jiahui Wang, Li Huang, Zhihong Zhao, Ronggen Wang, Haibin Long, Qingchun Ni, Haiying Liu, Minhua Hu, Junjiu Huang

Publication date: Available online 15 October 2025 Source: Experimental Eye Research Author(s): Manqi Pan, Zihao Chen, Xueliang Pan, He Zhang, Matthew Reilly, Sayoko E. Moroi, Jun Liu

Publication date: Available online 12 October 2025 Source: AJO International Author(s): Konstantinos G. Baroutis, Gustavo Sakuno, Sandra Hoyek, Nimesh A. Patel, Joan W. Miller, Demetrios G. Vavvas